Gene therapy clinical trials worldwide 1989-2004 - An overview

Journal of Gene Medicine

Volumn 6, Issue 6, 2004, Pages 597-602

  Edelstein, Michael L ^a   Abedi, Mohammad R ^b   Wixon, Jo ^c   Edelstein, Richard M ^c  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c John Wiley & Sons Inc United Kingdom   (United Kingdom)

Author keywords

Clinical trials; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; FIBROBLAST GROWTH FACTOR; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GENE PRODUCT; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 9 RECEPTOR; NAKED DNA; NEOMYCIN; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; RETROVIRUS VECTOR; SUICIDE SUBSTRATE; THYMIDINE KINASE; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

ANTIBIOTIC RESISTANCE; CANCER; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONFERENCE PAPER; DATA BASE; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEASIBILITY STUDY; GENE TRANSFER; GENETIC CODE; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; IN VIVO STUDY; INFORMATION PROCESSING; INTERNET; LEUKEMIA; MEDICAL LITERATURE; MELANOMA; MONOGENIC DISORDER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUBLISHING; REVIEW; RNA TRANSPORT; TREATMENT INDICATION; TUMOR ASSOCIATED LEUKOCYTE; UNITED STATES; VACCINIA VIRUS; VIRAL GENE THERAPY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ENZYMES; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC DISEASES, INBORN; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRODRUGS;

UNIDENTIFIED RETROVIRUS;

EID: 4444370799     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.619     Document Type: Review

References (21)

1. Journal of Gene Medicine Clinical Trials Website: http://www.wiley.co.uk/genmed/clinical.
2. Lederberg J. Molecular biology, eugenics and euphenics. Nature 1963; 198: 428-429.
3. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.
4. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
5. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
7. NIH/RAC site on Clinical Trials in Human Gene Transfer. Available: http://www4.od.nih.gov/oba/rac/clinicaltrial.htm.
8. UK Department of Health: Gene Therapy Advisory Committee. Available: http://www.doh.gov.uk/genetics/gtac/.
9. The Belgian Biosafety Server. Available: http://www.biosafety.be/GT/regulatory/GTtrials.html.
10. Zentrum Klinische Studien - University of Freiburg - German Somatic Gene Transfer Clinical Trial Database. Available: http://www.zks.uni-freiburg.de/dereg/register/index_en.php.
11. (Australian) Gene Therapy Research Advisory Panel (GTRAP). Available: http://www.health.gov.au/nhmrc/research/gtrap.htm.
12. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
13. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
14. Gansbacher B; European Society of Gene Therapy. Policy statement on the social, ethical and public awareness issues in gene therapy. J Gene Med 2002; 4: 687-691.
15. Gansbacher B; European Society of Gene Therapy. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT). J Gene Med 2003; 5: 261-262.
16. ASGT Policy/Position Statements. Available: http://www.asgt.org/positionstatements.shtml.
17. Kohn DB, Gansbacher B. Letter to the editors of Nature from the American Society of Gene Therapy (ASGT) and the European Society of Gene Therapy (ESGT). J Gene Med 2003; 5: 641.
18. Check E. Harmful potential of viral vectors fuels doubts over gene therapy. Nature 2003; 423: 573-574.
19. Cavazzana-Calvo M, Hacein-Bey S, Yates F, de Villartay JP, Le Deist F, Fischer A. Gene therapy of severe combined immunodeficiencies. J Gene Med 2001; 3: 201-206.
20. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
21. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995; 92: 11810-11813.